Want to see HK:1513 full AI Analyst Report?
Top Page
Livzon Pharmaceutical Group
(1513)
Select Model
Select Model
Rating:74Outperform
Price Target:
HK$25.00
â–˛(23.76% Upside)
Action:Reiterated
Date:10/27/26
Overall score reflects solid financial quality (strong margins, positive free cash flow, and moderate leverage) balanced against a near-term growth slowdown (TTM revenue contraction and easing returns). Technicals are moderately constructive but not fully long-term bullish (still below the 200-day average), while valuation is supportive with a moderate P/E and a high dividend yield.
Positive Factors
Strong Profitability
Healthy gross and net margins provide a durable earnings base for a specialty and generic pharmaceutical portfolio. This profitability can support continued research, commercialization, and shareholder distributions while giving the company resilience if revenue growth remains modest.
Negative Factors
Revenue Contraction
The extended pattern of weak or negative revenue growth points to a slower near-term expansion trajectory rather than a single-quarter fluctuation. Persistent top-line pressure could limit operating leverage, reduce reinvestment capacity, and make future earnings growth more dependent on margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
Healthy gross and net margins provide a durable earnings base for a specialty and generic pharmaceutical portfolio. This profitability can support continued research, commercialization, and shareholder distributions while giving the company resilience if revenue growth remains modest.
Read all positive factors
Livzon Pharmaceutical Group (1513) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$25.88B
Dividend Yield7.05%
Average Volume (3M)1.57M
Price to Earnings (P/E)15.9
Beta (1Y)0.69
Revenue Growth-9.56%
EPS Growth-23.22%
CountryHK
Employees8,878
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.75
Shares Outstanding299,807,130
10 Day Avg. Volume1,379,417
30 Day Avg. Volume1,566,015
Financial Highlights & Ratios
PEG Ratio8.43
Price to Book (P/B)1.65
Price to Sales (P/S)1.90
P/FCF Ratio9.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$36.80Price Target Upside82.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.91
Revenue Forecast (FY)HK$10.04B
Livzon Pharmaceutical Group Business Overview & Revenue Model
Company Description
Livzon Pharmaceutical Group Inc., founded in Zhuhai, China, in 1985, is a prominent enterprise dedicated to the research, development, manufacturing, and global commercialization of a wide range of pharmaceutical products, including finished drugs...
Livzon Pharmaceutical Group Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.17B | 12.02B | 11.81B | 12.43B | 12.63B | 12.06B |
| Gross Profit | 6.21B | 7.92B | 7.73B | 7.66B | 8.17B | 7.81B |
| EBITDA | 2.45B | 3.10B | 3.47B | 3.33B | 3.08B | 2.77B |
| Net Income | 1.55B | 2.02B | 2.06B | 1.95B | 1.91B | 1.78B |
Balance Sheet | ||||||
| Total Assets | 23.23B | 24.00B | 24.46B | 25.04B | 24.86B | 22.37B |
| Cash, Cash Equivalents and Short-Term Investments | 7.31B | 10.93B | 10.92B | 11.41B | 10.52B | 9.33B |
| Total Debt | 4.20B | 3.85B | 3.93B | 3.48B | 3.62B | 2.69B |
| Total Liabilities | 9.10B | 8.20B | 9.55B | 10.28B | 9.93B | 8.06B |
| Stockholders Equity | 13.01B | 13.89B | 13.86B | 14.04B | 13.88B | 13.00B |
Cash Flow | ||||||
| Free Cash Flow | 2.79B | 2.54B | 2.41B | 2.43B | 1.83B | 593.23M |
| Operating Cash Flow | 3.20B | 3.10B | 2.98B | 3.25B | 2.77B | 1.90B |
| Investing Cash Flow | -2.81B | -3.67B | -660.33M | -708.37M | -1.23B | -1.88B |
| Financing Cash Flow | -2.96B | -2.62B | -2.49B | -1.66B | -720.36M | -815.02M |
Livzon Pharmaceutical Group Technical Analysis
Positive
20.20
Price Trends
20.56
Positive
22.32
Negative
23.80
Negative
Market Momentum
0.32
Negative
58.98
Neutral
70.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1513, the sentiment is Positive. The current price of 20.2 is below the 20-day moving average (MA) of 21.10, below the 50-day MA of 20.56, and below the 200-day MA of 23.80, indicating a neutral trend. The MACD of 0.32 indicates Negative momentum. The RSI at 58.98 is Neutral, neither overbought nor oversold. The STOCH value of 70.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1513.
Livzon Pharmaceutical Group Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$25.88B | 15.90 | 11.32% | 7.05% | -9.56% | -23.22% | |
68 Neutral | HK$28.59B | 6.07 | 7.92% | 5.27% | 7.94% | 52.83% | |
61 Neutral | HK$24.03B | 13.50 | 8.60% | 3.49% | 14.80% | -2.88% | |
58 Neutral | HK$13.60B | 21.09 | 3.12% | 4.33% | -12.86% | -83.10% | |
58 Neutral | HK$15.42B | 13.56 | 6.61% | 3.89% | 7.35% | -45.49% | |
57 Neutral | HK$35.15B | 12.36 | 6.64% | 6.68% | 6.00% | -23.05% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
HK:1513
Livzon Pharmaceutical Group
22.08
-5.38
-19.58%
HK:3933
The United Laboratories International Holdings
6.91
-5.41
-43.91%
HK:0867
China Medical System Holdings
9.85
-3.02
-23.47%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
12.91
-4.07
-23.95%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.55
-0.18
-3.87%
HK:0512
Grand Pharmaceutical Group Limited
4.35
-3.51
-44.70%
Livzon Pharmaceutical Group Corporate Events
Livzon MABPharm Wins NMPA Nod for Next-Generation Anti-FXI Anticoagulant Trial
Oct 27, 2026
Livzon Pharmaceutical Group’s subsidiary Livzon MABPharm has received approval from China’s National Medical Products Administration to begin clinical trials of a Class 1 recombinant humanized anti-FXI bispecific antibody injection. Th...
Livzon Unit Wins NMPA Nod for Trial of New Vestibular Migraine Remedy
Oct 27, 2026
Livzon’s subsidiary Sichuan Guangda has received approval from China’s National Medical Products Administration to begin clinical trials of Tiange Dingxuan Granules, a Class 1.1 traditional Chinese medicine designed to treat vestibular...
Livzon Unit Wins NMPA Approval for Classical TCM Wandai Tang Granules
Oct 27, 2026
Livzon Pharmaceutical Group’s subsidiary Sichuan Guangda Pharmaceutical Manufacturing has obtained Chinese regulatory approval to market Wandai Tang Granules, a Class 3.1 traditional Chinese medicine derived from a classical gynecological pr...
Livzon Pharma Sets Q3 2026 Dividend Plan for A and H Shareholders
Oct 23, 2026
Livzon Pharmaceutical Group’s board has approved a profit distribution plan for the third quarter of 2026 and will put an ordinary resolution to shareholders at an extraordinary general meeting to seek formal approval. The plan is based on t...
Livzon Pharmaceutical Declares Third-Quarter Cash Dividend for 2026
Oct 23, 2026
Livzon Pharmaceutical Group has declared an ordinary third-quarter cash dividend of RMB 12.39 per 10 shares for the period ended 30 September 2026, reinforcing its shareholder return policy and signaling solid cash generation. The dividend on H sh...
Livzon Pharmaceutical Sees Profit and Revenue Drop in Q3 2026
Oct 23, 2026
Livzon Pharmaceutical Group reported a sharp downturn in its 2026 third-quarter performance, with operating income for July to September falling 18.44% year-on-year to RMB 2.32 billion and net profit attributable to shareholders dropping 24.76% to...
Livzon Pharmaceutical Sets EGM to Approve Dividend and Long-Term Shareholder Return Plan
Oct 23, 2026
Livzon Pharmaceutical Group has called its 2026 second extraordinary general meeting for 12 November in Zhuhai, where shareholders will vote on appointing Ms. Zhu Linlin as a non-executive director, a profit distribution plan for the third quarter...
Livzon Pharmaceutical Group Unveils Three-Year Shareholder Return Plan
Oct 23, 2026
Livzon Pharmaceutical Group has approved a shareholder return plan covering 2026 to 2028, aimed at optimizing its profit distribution policy and formalizing a more scientific, sustained and stable mechanism for returning value to investors. The pl...
Livzon Pharmaceutical Schedules Board Meeting to Review Q3 Results and Potential Dividend
Oct 12, 2026
Livzon Pharmaceutical Group Inc. has scheduled a board meeting for 23 October 2026 to review and approve its unaudited third-quarter results for the nine months ended 30 September 2026. The board will also consider whether to declare a dividend fo...
Livzon Pharmaceutical Addresses Unusual Share Price Volatility
Sep 29, 2026
Livzon Pharmaceutical Group Inc., a dual-listed pharmaceutical company in Shenzhen and Hong Kong, develops and sells healthcare products for the Chinese and broader regional markets. With a diversified board and adherence to mainland and Hong Kong...
Livzon Wins NMPA Approval for Three‑Month Leuprorelin Microsphere Injection
Sep 29, 2026
Shanghai Livzon Pharmaceutical Manufacturing, a subsidiary of Livzon Pharmaceutical Group, has obtained National Medical Products Administration approval in China for marketing a new 11.25 mg three‑month formulation of Leuprorelin Acetate Mi...
Livzon Pharma Updates Terms of 2026 Special Interim Dividend
Sep 25, 2026
Livzon Pharmaceutical Group Inc. has announced an updated special interim cash dividend to reward shareholders, declaring RMB 10.2 per 10 shares, equivalent to HKD 11.85 per 10 shares after an exchange rate adjustment. The update clarifies the RMB...
Livzon Pharmaceutical Shareholders Approve EGM Resolution, Clearing Way for Special Dividend
Sep 24, 2026
Livzon Pharmaceutical Group reported that its 2026 First Extraordinary General Meeting, held in Zhuhai on 24 September, successfully passed the sole resolution by poll. The meeting saw participation from holders and proxies representing 440,351,82...
Livzon Pharmaceutical Announces Special Interim Dividend for H Shareholders
Sep 24, 2026
Livzon Pharmaceutical Group has declared a special interim cash dividend of RMB 10.2 per 10 shares, with Hong Kong holders to receive HKD 11.85 per 10 shares based on an exchange rate of RMB 1 to HKD 0.86054. The move, approved on 24 September 202...
Livzon Pharmaceutical Vice President Resigns but Remains in Company Role
Sep 24, 2026
Livzon Pharmaceutical Group has announced that Mr. Xu Xiao has resigned from his role as vice president due to work adjustments, though he will remain in other positions within the company. The board emphasized that the move will not affect the co...
Livzon Proposes New Non-Executive Director With Strong Pet Pharma Credentials
Sep 18, 2026
Livzon Pharmaceutical Group has proposed appointing Ms. Zhu Linlin as a non-executive director for the current board term, subject to approval at an upcoming extraordinary general meeting. Upon approval, she will enter into a director’s serv...
Livzon Pharmaceutical Chairman Retires as President Liu Daping Takes Helm
Sep 11, 2026
Livzon Pharmaceutical Group has announced the retirement of long-serving chairman and non-executive director Zhu Baoguo, who is also stepping down from key board committee roles and as the company’s legal representative. Despite leaving all ...
Livzon Pharmaceutical Sets Out Board and Committee Structure
Sep 11, 2026
Livzon Pharmaceutical Group Inc. has detailed the current composition of its board of directors, which includes executive, non-executive, independent and an employee representative director. The board is chaired by President Mr. Liu Daping, with V...
Livzon Pharmaceutical Announces RMB 905 Million Special Interim Dividend
Sep 8, 2026
Livzon Pharmaceutical Group plans to distribute a 2026 special interim dividend to shareholders, reflecting strong operating conditions, high accumulated undistributed profits and ample monetary funds. The board believes using the company’s ...
Livzon Pharma Calls EGM to Approve Cross-Border Special Interim Dividend
Sep 8, 2026
Livzon Pharmaceutical Group has called its first extraordinary general meeting of 2026 for 24 September in Zhuhai to seek shareholder approval for a special interim dividend. The meeting will be conducted by poll under Hong Kong listing rules, wit...
Livzon Pharmaceutical Group Declares Special Interim Dividend for 2026
Sep 8, 2026
Livzon Pharmaceutical Group Inc., a Hong Kong-listed pharmaceutical issuer under stock code 01513, has announced a special interim cash dividend to reward its shareholders. The company has set Tricor Investor Services Limited as its share registra...
Livzon Pharmaceutical Sets Record Date for September 2026 Extraordinary General Meeting
Sep 3, 2026
Livzon Pharmaceutical Group has scheduled its first extraordinary general meeting of 2026 for 2:00 p.m. on 24 September 2026 in Zhuhai, Guangdong. The record date to determine shareholders’ eligibility to attend and vote is set for 18 Septem...
Livzon Wins NMPA Nod for Innovative Psoriasis Biologic Lecankitug
Aug 27, 2026
Livzon Pharmaceutical Group’s subsidiary Livzon MAB Pharm has obtained National Medical Products Administration approval in China for Lecankitug Injection, a Class 1 innovative therapeutic biological product jointly developed with Beijing Xi...
Livzon Pharmaceutical Plans Board Meeting to Consider Special Dividend
Aug 27, 2026
Livzon Pharmaceutical Group Inc., a Hong Kong-listed Chinese drugmaker, plans to convene its board on 8 September 2026 to consider a special dividend distribution for shareholders. The move underscores the company’s focus on capital manageme...
Livzon Pharma Raises Stake in Xinbeijiang Unit Through Connected Share Deal
Aug 21, 2026
Livzon Pharmaceutical Group has agreed to acquire approximately 3.50% of the shares in Xinbeijiang Pharma from Zhong Hui Yuan for about RMB 106.70 million in cash. Upon completion, Livzon’s direct shareholding in Xinbeijiang Pharma will rise...
Livzon Pharmaceutical Group Publishes Unaudited 2026 Interim Results
Aug 21, 2026
Livzon Pharmaceutical Group has released its unaudited interim results for the six months ended 30 June 2026, providing shareholders and investors with a comprehensive update on its mid‑year financial and operational performance. The full in...
Livzon Pharmaceutical Schedules Board Meeting for Interim Results Review
Aug 6, 2026
Livzon Pharmaceutical Group has scheduled a board meeting for 21 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026. The meeting will also address other business matters, signaling the next formal...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.